Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
종목 코드 JUNS
회사 이름Jupiter Neurosciences Inc
상장일Dec 03, 2024
설립일2016
CEOMr. Christer Rosen
직원 수4
유형Ordinary Share
회계 연도 종료Dec 03
주소1001 North US HWY 1, Suite 504
도시PALM BEACH GARDENS
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호33477
전화15614066154
웹사이트https://jupiterneurosciences.com/
종목 코드 JUNS
상장일Dec 03, 2024
설립일2016
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음